(19)
(11) EP 3 504 967 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
28.08.2019 Bulletin 2019/35

(43) Date of publication:
03.07.2019 Bulletin 2019/27

(21) Application number: 18203606.1

(22) Date of filing: 05.05.2010
(51) International Patent Classification (IPC): 
A01N 43/04(2006.01)
A61K 9/127(2006.01)
A61K 47/69(2017.01)
 A61K 31/70(2006.01)
A61K 31/713(2006.01)
A61P 19/02(2006.01)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 05.05.2009 US 17577709 P
15.09.2009 US 24276109 P
14.08.2009 US 23404509 P
15.10.2009 US 25199109 P
06.11.2009 US 25884809 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
10772775.2 / 2416652

(71) Applicant: Arbutus Biopharma Corporation
Burnaby, BC V5J 5J8 (CA)

(72) Inventors:
  • NOVOBRANTSEVA, Tatiana
    Cambridge, MA Massachusetts 02142 (US)
  • AKINC, Akin
    Cambridge, MA Massachusetts 02142 (US)
  • SUGO, Tsukasa
    Cambridge, MA Massachusetts 02142 (US)

(74) Representative: Müller-Boré & Partner Patentanwälte PartG mbB 
Friedenheimer Brücke 21
80639 München
80639 München (DE)

 
Remarks:
This application was filed on 31-10-2018 as a divisional application to the application mentioned under INID code 62.
Remarks:
Claims filed after the date of receipt of the divisonal application (Rule 68(4) EPC).
 


(54) METHODS OF DELIVERING OLIGONUCLEOTIDES TO IMMUNE CELLS


(57) The invention relates to the field of delivery of nucleic acid-based agents to immune cells.